Hepatitis C Support Group
Hepatitis C is a blood-borne viral disease which can cause liver inflammation, fibrosis, cirrhosis and liver cancer. The hepatitis C virus (HCV) is spread by blood-to-blood contact with an infected person's blood. Many people with HCV infection have no symptoms and are unaware of the need to seek treatment. Hepatitis C infects an estimated 150-200 million people worldwide.
inShare.3
Share this
Email
Print
Related News
Gilead bags blood disorder drug with YM BioSciences buy
Wed, Dec 12 2012
Related Topics
Health
Mon Jan 7, 2013 9:39am EST
(Reuters) - Gilead Sciences Inc is on track to file for regulatory approval of sofosbuvir, its treatment for chronic hepatitis C virus (HCV) infection, starting in mid-2013, the biotech company said on Monday.
Gilead is scheduled to give investors an update on its candidates for HCV treatment at a JPMorgan healthcare conference this week in San Francisco.
The company will discuss new results from an arm of a continuing Phase 2 trial and provide a progress report on a range of Phase 2 and 3 trials evaluating a once-daily fixed-dose combination tablet of the medicines.
How succesful? How bad are the side effects?
The urgency is not only for investors and profit but also the huge financial burden of livers of Interferon non responder's crashing and hospitals being over burdened and insurance claims sky rocketing.
It will happen this year...
http://hcvadvocate.blogspot.ca/search?q=sofosbuvir+results
Geno 2 and 3 do well on 12 weeks of Sofosbuvier with Interferon and Riba and only about 60% without Interferon